Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$221.72 ▼ -1.04
(-0.47%)
MKT CAP: $88.93B • VOL: 9.01M
52W L $22 52W H $254
MRNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.94B | $3.24B | $6.85B |
| YoY Revenue Growth % | -39.9% | -52.7% | — |
| Gross Profit | $1.08B | $1.77B | — |
| Gross Margin % | 55.3% | 54.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.07B | -$3.94B | -$4.24B |
| Operating Margin % | -158.1% | -121.9% | -61.9% |
| Net Income (GAAP) | -$2.82B | -$3.56B | -$4.71B |
| EBITDA (Normalized) | -$2.92B | -$3.10B | -$3.99B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.87B | -$3.00B | -$3.12B |
| Capital Expenditures (CapEx) | $192.0M | $1.05B | $308.2M |
| Free Cash Flow (FCF) | -$2.06B | -$4.05B | -$3.43B |
| FCF Margin % | -106.2% | -125.3% | -50.0% |
| Return on Invested Capital (ROIC %) | -36.5% | -34.7% | -11.3% |
| Cash & Short-Term Equivalents | $2.60B | $1.93B | — |
| Total Debt (Short + Long Term) | $590.0M | $0 | $11.45B |
| Total Stockholders' Equity | $8.65B | $10.90B | $23.48B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MRNA.